Baricent 2 mg Tablet


Baricent 2 mg Tablet

Introduction to Baricent 2 mg (Baricitinib)

Baricent 2 mg, meticulously developed by Incepta Pharmaceuticals Ltd and supplied by Orio Pharma, represents a significant advancement in the treatment of rheumatoid arthritis. Baricitinib, the active ingredient in Baricent, offers a targeted approach to managing the symptoms and progression of rheumatoid arthritis, providing hope and improved quality of life for patients.

Description: Baricent 2 mg (Baricitinib)

Baricent 2 mg contains Baricitinib, a Janus kinase (JAK) inhibitor. This medication specifically targets and inhibits the activity of Janus kinases, which play a crucial role in the inflammatory process associated with rheumatoid arthritis.

Mechanism of Action

Baricitinib works by selectively inhibiting JAK1 and JAK2 enzymes. By blocking these pathways, Baricent 2 mg reduces the production of inflammatory mediators, thereby decreasing inflammation and pain, and preventing joint damage.

Clinical Use

Baricent 2 mg is primarily prescribed for:

  • Rheumatoid Arthritis: Used to treat moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

Dosage and Administration

The recommended dosage of Baricent 2 mg is determined by healthcare professionals based on the severity of the condition and the patient’s response to treatment. Administered orally, it is crucial to follow the prescribed regimen to achieve optimal results.

Benefits of Baricent 2 mg (Baricitinib)

  • Effective Inflammation Control: Reduces inflammation and alleviates pain associated with rheumatoid arthritis.
  • Prevention of Joint Damage: Helps to prevent the progression of joint damage and maintains joint function.
  • Improved Quality of Life: Enhances the overall quality of life by managing symptoms effectively.

Manufacturer: Incepta Pharmaceuticals Ltd

Incepta Pharmaceuticals Ltd is renowned for producing high-quality medications. Their commitment to innovation and rigorous quality control ensures that Baricent 2 mg meets the highest standards of efficacy and safety.

Supplier: Orio Pharma

Orio Pharma ensures that Baricent 2 mg is accessible to healthcare providers and patients worldwide. Their dedication to excellence in distribution guarantees timely and reliable access to this essential medication.


In conclusion, Baricent 2 mg (Baricitinib) is a groundbreaking medication for the management of rheumatoid arthritis. Manufactured by Incepta Pharmaceuticals Ltd and supplied by Orio Pharma, this treatment offers a targeted and effective approach to managing this chronic condition.

The inhibition of JAK1 and JAK2 enzymes by Baricitinib highlights its role as a potent and well-tolerated therapeutic option. The collaboration between Incepta Pharmaceuticals Ltd and Orio Pharma ensures the highest standards of manufacturing and distribution, making Baricent 2 mg a reliable and accessible option for patients seeking better health outcomes in their battle against rheumatoid arthritis.